Sellas Life Sciences reports wider loss as REGAL trial nears final analysis

Sellas Life Sciences Group (SLS) reported a wider second-quarter loss as the cancer-drug developer increased spending ahead ...
The American Journal of Managed Care

In Final CEPHEUS Analysis for Myeloma, Median PFS Not Reached After More Than 6 Years

Final CEPHEUS transplant-ineligible analysis showed 72-month PFS of 59.3% with DVRd versus 38.3% with VRd; median PFS was unreached versus 50.2 months (HR 0.55). MRD negativity improved with DVRd at ...
ascopubs.org

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized ...

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial We report results of the final analysis of ...
The New England Journal of Medicine

Iptacopan in IgA Nephropathy — Final 24-Month Data

Overactivation of the alternative complement pathway contributes to IgA nephropathy and glomerular inflammation. In the 9-month interim analysis of this phase 3 trial, iptacopan, a complement factor B ...